Skip to content
PEPLUX

GHK-Cu + BPC-157 + TB-500 fragment blend

GLOW Stack

Illustrative PEPLUX product vial in a purple-lit studio
Product illustration

Product form

Subcutaneous injection

The process

Licensed provider review

GLOW Stack cost

$229 per month

*If medically eligible.
Medication
Included
Clinician visit
Included
Baseline labs
Included
Lab retests
Included when ordered by your provider
Shipping
Included
Patient portal access
Included
Care-team chat support
Included

Considering more than one product?

  • Two products prescribed together: $349 per month
  • Three products prescribed together: $479 per month
Compare pricing

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

FDA status, checked on October 13, 2026

The GLOW Stack combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.

Prescription products require an online evaluation with a licensed provider. Not all patients qualify.

States served: not yet confirmed. How state availability works

What is GLOW Stack?

BPC-157, GHK-Cu and TB-500. TB-500 refers to the LKKTETQ fragment, not full-length thymosin beta-4. The dispensing pharmacy must confirm every ingredient and its formulation before ordering is enabled.

Adults seeking a provider discussion about this three-ingredient mixture, with its evidence limitations and risks reviewed before any decision. The catalog name is not a claim about appearance or outcomes.

Key risks

  • The safety of this particular mixture in people has not been established. Combining ingredients can introduce effects and interactions that studies of one ingredient do not capture.
  • Immune reactions, including allergic reactions to a peptide or an impurity, are possible. The frequency and longer-term risks are not established.
All risks and who should not use it

FDA status

FDA status for GLOW Stack.

Rendered from our regulatory records, which cite FDA, Federal Register and label documents directly. Each record shows the date we last checked it.

No compounding pathway today.

The GLOW Stack combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

An FDA advisory committee recommendation is not a listing. Nothing changes unless FDA publishes a final rule.

BPC-157

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

BPC-157 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nominations were withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 23, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule.

Basis
FDA's 503A categories document of April 15, 2026 announced the removal of BPC-157 from Category 2, effective seven days later, because its nominations were withdrawn. It has no entry in FDA's current 503A or 503B category documents, it is not on the 503A bulks list (21 CFR 216.23) or the 503B bulks list, and it is not a component of an FDA-approved drug. FDA's safety page says compounded BPC-157 may pose a risk of immunogenicity and that FDA has identified no, or only limited, safety-related information for the proposed routes of administration.
Checked on
October 13, 2026

GHK-Cu

FDA interim enforcement discretion (Category 1). Not a listing. Not FDA-approved.

GHK-Cu for non-injectable use, such as topical, is in FDA's 503A Category 1. FDA is still evaluating it and has said it does not intend to take action against a 503A pharmacy that compounds it against a patient-specific prescription while the interim policy's conditions are met. That is enforcement discretion, not a listing, and it has already been withdrawn once. Injectable GHK-Cu has no compounding pathway. Compounded GHK-Cu is not FDA-approved. FDA does not check the safety, effectiveness or quality of compounded drugs before they are sold.

FDA's Category 1 entry reads "GHK-Cu (except for injectable routes of administration)". It covers non-injectable routes, such as topical use, only. Subcutaneous, intramuscular and intravenous GHK-Cu are outside it.

Basis
FDA's 503A categories document (updated May 14, 2026) lists "GHK-Cu (except for injectable routes of administration)" in Category 1, bulk drug substances under evaluation. FDA removed GHK-Cu from Category 1 on April 22, 2026 after its nominations were withdrawn. On May 5, 2026 one nominator clarified that it meant to withdraw only the injectable route, and FDA added the non-injectable entry back. GHK-Cu is not in any 503B category and is not on the 503A bulks list in 21 CFR 216.23. Category 1 is FDA's interim enforcement discretion, not a statutory pathway.
Checked on
October 13, 2026

Thymosin beta-4, fragment (LKKTETQ)

No compounding pathway today. An FDA advisory committee recommendation is not a listing.

TB-500 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nomination was withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 23, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule.

TB-500 is the LKKTETQ fragment of thymosin beta-4, not full-length thymosin beta-4. The two have separate status records, and the status of one does not transfer to the other.

Basis
FDA's 503A categories document of April 15, 2026 announced the removal of thymosin beta-4 fragment (LKKTETQ) from Category 2, effective seven days later, because its nomination was withdrawn. It has no entry in FDA's current 503A or 503B category documents, it is not on the 503A bulks list (21 CFR 216.23) or the 503B bulks list, and it is not a component of an FDA-approved drug. FDA's safety page says it has not identified any human exposure data for drug products containing the fragment and lacks important information on whether it would cause harm in people.
Checked on
October 13, 2026

How it works

GLOW Stack mechanism.

GLOW is the catalog name for an intended mixture of GHK-Cu, BPC-157 and the LKKTETQ fragment associated with TB-500. GHK-Cu is a copper-binding tripeptide. TB-500 refers here to a fragment, not full-length thymosin beta-4. The prescriber and pharmacy must confirm each ingredient and the final formulation.

That describes what the molecule does in the body. It is not a claim about what it will do for you.

What the evidence supports

GLOW Stack: evidence and limitations.

Evidence from studies of topical GHK-Cu or of a single peptide cannot establish the effects of this injected combination. Published human evidence for BPC-157 is limited. The cited safety review reports no identified human exposure data for products containing the TB-500 fragment. PEPLUX has not verified clinical evidence that establishes the safety or effectiveness of this mixture.

Risks

GLOW Stack risks and side effects.

  • The safety of this particular mixture in people has not been established. Combining ingredients can introduce effects and interactions that studies of one ingredient do not capture.
  • Immune reactions, including allergic reactions to a peptide or an impurity, are possible. The frequency and longer-term risks are not established.
  • Injection can cause pain, redness, swelling or bruising. Infection is possible if the product or injection technique is not sterile.
  • Safety information is insufficient for use during pregnancy or breastfeeding or in people under 18. These groups should not use this product.
  • Seek urgent medical care for trouble breathing, swelling of the face or throat, or other signs of a serious allergic reaction.
  • A copper-containing product requires specific review for anyone with Wilson's disease or another disorder of copper metabolism, or a known copper allergy.

This information is educational and is not medical advice. It does not establish a provider–patient relationship.

Clinical review

What your prescriber will consider.

These are decision factors a licensed provider weighs when deciding whether this product is appropriate for you. They are not instructions, and there is no dosing protocol on this page.

  • The exact identity of each ingredient, the intended formulation and route, and documentation from the prescriber and pharmacy before any treatment decision

  • All prescription medicines, supplements and other peptide products, because interactions between the ingredients are not established

  • Any prior allergic or immune reaction, current medical condition, pregnancy, breastfeeding or plans to conceive

  • Whether an established treatment should be considered first, and any applicable anti-doping rules

  • Copper allergy or sensitivity, and any disorder affecting copper metabolism

PEPLUX does not publish self-administration protocols. Dose, frequency and duration are set by your prescriber against your own history and reviewed over time.

Lot documents

What a certificate of analysis should cover.

When a pharmacy is named, each lot's certificate of analysis is expected to cover the tests below. No certificate exists or is published yet.

  • Potency
  • Sterility
  • Endotoxin
  • pH

Sport and anti-doping

Prohibited under the WADA code.

  • BPC-157: Prohibited at all times under WADA class S0 (non-approved substances).
  • GHK-Cu: Not named on the WADA 2026 Prohibited List.
  • Thymosin beta-4, fragment (LKKTETQ): Prohibited at all times under WADA class S2.3 (growth factors and growth factor modulators).

If you compete under an anti-doping authority, or are tested through your employer or federation, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.

Straight answers

Common questions about GLOW Stack.

What is the FDA status of GLOW Stack?
No compounding pathway today. BPC-157: BPC-157 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nominations were withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 23, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule. Checked against primary sources on October 13, 2026. GHK-Cu: GHK-Cu for non-injectable use, such as topical, is in FDA's 503A Category 1. FDA is still evaluating it and has said it does not intend to take action against a 503A pharmacy that compounds it against a patient-specific prescription while the interim policy's conditions are met. That is enforcement discretion, not a listing, and it has already been withdrawn once. Injectable GHK-Cu has no compounding pathway. Compounded GHK-Cu is not FDA-approved. FDA does not check the safety, effectiveness or quality of compounded drugs before they are sold. Checked against primary sources on October 13, 2026. Thymosin beta-4, fragment (LKKTETQ): TB-500 is not FDA-approved, and there is no pathway for a US pharmacy to compound it today. FDA removed it from its 503A Category 2 in April 2026 after the nomination was withdrawn, but removal is not a listing. FDA's Pharmacy Compounding Advisory Committee recommended it on July 23, 2026. A recommendation is not a listing: nothing changes unless FDA publishes a final rule. Checked against primary sources on October 13, 2026.
Is compounded GLOW Stack an approved drug?
No. Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality. The GLOW Stack combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established. PEPLUX is a telehealth platform, not a pharmacy or drug manufacturer. Medications are compounded and dispensed by independently licensed US compounding pharmacies.
What does the evidence support for GLOW Stack, and what does it not?
Evidence from studies of topical GHK-Cu or of a single peptide cannot establish the effects of this injected combination. Published human evidence for BPC-157 is limited. The cited safety review reports no identified human exposure data for products containing the TB-500 fragment. PEPLUX has not verified clinical evidence that establishes the safety or effectiveness of this mixture.
What are the risks of GLOW Stack?
The safety of this particular mixture in people has not been established. Combining ingredients can introduce effects and interactions that studies of one ingredient do not capture. The full list of side effects, and of who should not use GLOW Stack, is in the risks section of this page. Your prescriber reviews your history before deciding whether it is appropriate for you.
Does GLOW Stack require baseline labs?
Your prescriber determines whether baseline labs are needed before considering GLOW Stack. Baseline labs are included in the price.
What does GLOW Stack cost?
$229 per month. Medication: included. Clinician visit: included. Baseline labs: included. Lab retests: included when ordered by your provider. Shipping: included. Patient portal access: included. Care-team chat support: included. *If medically eligible.
Is GLOW Stack prohibited in sport?
BPC-157: Prohibited at all times under WADA class S0 (non-approved substances). GHK-Cu: Not named on the WADA 2026 Prohibited List. Thymosin beta-4, fragment (LKKTETQ): Prohibited at all times under WADA class S2.3 (growth factors and growth factor modulators). If you are subject to anti-doping testing, tell your prescriber before you start. Sanctions can follow from possession or purchase records alone, without a positive test.
How is GLOW Stack given?
Subcutaneous injection. Your prescriber decides whether it is appropriate for you and sets the regimen. PEPLUX does not publish dosing.

Next step

A licensed provider reviews every request.

The GLOW Stack combination is not FDA-approved, and there is no lawful pathway for a US pharmacy to compound it today. Its safety and effectiveness in people have not been established.

Order now

No compounding pathway today.

*If medically eligible.

Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality.

Also offered

Other products.

All productsFDA status tracker